4YD Stock Overview
A nanotechnology company, develops, manufactures, and sells nanoporous silica particles for life science industry in China, India, the United State of America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Nanologica AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.079 |
| 52 Week High | SEK 0.53 |
| 52 Week Low | SEK 0.045 |
| Beta | 0.44 |
| 1 Month Change | 54.90% |
| 3 Month Change | -45.70% |
| 1 Year Change | -84.20% |
| 3 Year Change | -94.53% |
| 5 Year Change | n/a |
| Change since IPO | -95.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4YD | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -7.9% | -1.4% | -0.9% |
| 1Y | -84.2% | -12.5% | 14.1% |
Return vs Industry: 4YD underperformed the German Biotechs industry which returned -13.4% over the past year.
Return vs Market: 4YD underperformed the German Market which returned 15.8% over the past year.
Price Volatility
| 4YD volatility | |
|---|---|
| 4YD Average Weekly Movement | 29.8% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 4YD's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4YD's weekly volatility has increased from 19% to 30% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 16 | Andreas Bhagwani | www.nanologica.com |
Nanologica AB (publ), a nanotechnology company, develops, manufactures, and sells nanoporous silica particles for life science industry in China, India, the United State of America, and internationally. It offers NLAB Saga, a new generation silica for preparative chromatography; and SVEA, a pre-packaged columns for analytical chromatography; and high-performance liquid chromatography, a separation method based on different substances in a solution passing through a column at different paces. The company provides products for the analysis and purification of substances, with a focus on peptides drugs for the treatment of diabetes and obesity.
Nanologica AB (publ) Fundamentals Summary
| 4YD fundamental statistics | |
|---|---|
| Market cap | €8.90m |
| Earnings (TTM) | -€5.46m |
| Revenue (TTM) | €1.87m |
Is 4YD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4YD income statement (TTM) | |
|---|---|
| Revenue | SEK 20.25m |
| Cost of Revenue | SEK 16.75m |
| Gross Profit | SEK 3.50m |
| Other Expenses | SEK 62.53m |
| Earnings | -SEK 59.03m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Jul 10, 2025
| Earnings per share (EPS) | -0.67 |
| Gross Margin | 17.28% |
| Net Profit Margin | -291.48% |
| Debt/Equity Ratio | 74.8% |
How did 4YD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 11:42 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nanologica AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Filip Einarsson | Redeye |